Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Allogeneic
1.2.3 Autologous
1.3 Market by Application
1.3.1 Global CAR-T Therapy in Haematological Malignancy Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-T Therapy in Haematological Malignancy Market Perspective (2018-2033)
2.2 CAR-T Therapy in Haematological Malignancy Growth Trends by Region
2.2.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Size by Region (2018-2023)
2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Region (2024-2033)
2.3 CAR-T Therapy in Haematological Malignancy Market Dynamics
2.3.1 CAR-T Therapy in Haematological Malignancy Industry Trends
2.3.2 CAR-T Therapy in Haematological Malignancy Market Drivers
2.3.3 CAR-T Therapy in Haematological Malignancy Market Challenges
2.3.4 CAR-T Therapy in Haematological Malignancy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue
3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2018-2023)
3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2018-2023)
3.2 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
3.4 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio
3.4.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2022
3.5 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served
3.6 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
3.7 Date of Enter into CAR-T Therapy in Haematological Malignancy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-T Therapy in Haematological Malignancy Breakdown Data by Type
4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2018-2023)
4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2024-2033)
5 CAR-T Therapy in Haematological Malignancy Breakdown Data by Application
5.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2018-2023)
5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2018-2033)
6.2 North America CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2018-2033)
7.2 Europe CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size (2018-2033)
8.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023)
8.4 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-T Therapy in Haematological Malignancy Market Size (2018-2033)
9.2 Latin America CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
9.4 Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size (2018-2033)
10.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023)
10.4 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene (Juno Therapeutics)
11.1.1 Celgene (Juno Therapeutics) Company Detail
11.1.2 Celgene (Juno Therapeutics) Business Overview
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
11.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.1.5 Celgene (Juno Therapeutics) Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
11.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Gilead (Kite Pharma)
11.3.1 Gilead (Kite Pharma) Company Detail
11.3.2 Gilead (Kite Pharma) Business Overview
11.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
11.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.3.5 Gilead (Kite Pharma) Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
11.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 CARsgen Therapeutics
11.5.1 CARsgen Therapeutics Company Detail
11.5.2 CARsgen Therapeutics Business Overview
11.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.5.5 CARsgen Therapeutics Recent Development
11.6 Autolus Therapeutics
11.6.1 Autolus Therapeutics Company Detail
11.6.2 Autolus Therapeutics Business Overview
11.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.6.5 Autolus Therapeutics Recent Development
11.7 Aurora BioPharma
11.7.1 Aurora BioPharma Company Detail
11.7.2 Aurora BioPharma Business Overview
11.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction
11.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.7.5 Aurora BioPharma Recent Development
11.8 Sorrento Therapeutics
11.8.1 Sorrento Therapeutics Company Detail
11.8.2 Sorrento Therapeutics Business Overview
11.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.8.5 Sorrento Therapeutics Recent Development
11.9 Mustang Bio
11.9.1 Mustang Bio Company Detail
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction
11.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.9.5 Mustang Bio Recent Development
11.10 Bluebird Bio
11.10.1 Bluebird Bio Company Detail
11.10.2 Bluebird Bio Business Overview
11.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction
11.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.10.5 Bluebird Bio Recent Development
11.11 Collectis
11.11.1 Collectis Company Detail
11.11.2 Collectis Business Overview
11.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction
11.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.11.5 Collectis Recent Development
11.12 Allogene Therapeutics
11.12.1 Allogene Therapeutics Company Detail
11.12.2 Allogene Therapeutics Business Overview
11.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
11.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.12.5 Allogene Therapeutics Recent Development
11.13 Celyad
11.13.1 Celyad Company Detail
11.13.2 Celyad Business Overview
11.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction
11.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
11.13.5 Celyad Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Allogeneic
Table 3. Key Players of Autologous
Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global CAR-T Therapy in Haematological Malignancy Market Share by Region (2018-2023)
Table 8. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global CAR-T Therapy in Haematological Malignancy Market Share by Region (2024-2033)
Table 10. CAR-T Therapy in Haematological Malignancy Market Trends
Table 11. CAR-T Therapy in Haematological Malignancy Market Drivers
Table 12. CAR-T Therapy in Haematological Malignancy Market Challenges
Table 13. CAR-T Therapy in Haematological Malignancy Market Restraints
Table 14. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2018-2023)
Table 16. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2022)
Table 17. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
Table 21. Date of Enter into CAR-T Therapy in Haematological Malignancy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2018-2023)
Table 25. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2024-2033)
Table 27. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2018-2023)
Table 29. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2024-2033)
Table 31. North America CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size by Country (2024-2033) & (US$ Million)
Table 46. Celgene (Juno Therapeutics) Company Detail
Table 47. Celgene (Juno Therapeutics) Business Overview
Table 48. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product
Table 49. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 50. Celgene (Juno Therapeutics) Recent Development
Table 51. Novartis Company Detail
Table 52. Novartis Business Overview
Table 53. Novartis CAR-T Therapy in Haematological Malignancy Product
Table 54. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Gilead (Kite Pharma) Company Detail
Table 57. Gilead (Kite Pharma) Business Overview
Table 58. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product
Table 59. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 60. Gilead (Kite Pharma) Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer CAR-T Therapy in Haematological Malignancy Product
Table 64. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. CARsgen Therapeutics Company Detail
Table 67. CARsgen Therapeutics Business Overview
Table 68. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 69. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 70. CARsgen Therapeutics Recent Development
Table 71. Autolus Therapeutics Company Detail
Table 72. Autolus Therapeutics Business Overview
Table 73. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 74. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 75. Autolus Therapeutics Recent Development
Table 76. Aurora BioPharma Company Detail
Table 77. Aurora BioPharma Business Overview
Table 78. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product
Table 79. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 80. Aurora BioPharma Recent Development
Table 81. Sorrento Therapeutics Company Detail
Table 82. Sorrento Therapeutics Business Overview
Table 83. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 84. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 85. Sorrento Therapeutics Recent Development
Table 86. Mustang Bio Company Detail
Table 87. Mustang Bio Business Overview
Table 88. Mustang Bio CAR-T Therapy in Haematological Malignancy Product
Table 89. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 90. Mustang Bio Recent Development
Table 91. Bluebird Bio Company Detail
Table 92. Bluebird Bio Business Overview
Table 93. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product
Table 94. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 95. Bluebird Bio Recent Development
Table 96. Collectis Company Detail
Table 97. Collectis Business Overview
Table 98. Collectis CAR-T Therapy in Haematological Malignancy Product
Table 99. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 100. Collectis Recent Development
Table 101. Allogene Therapeutics Company Detail
Table 102. Allogene Therapeutics Business Overview
Table 103. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product
Table 104. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 105. Allogene Therapeutics Recent Development
Table 106. Celyad Company Detail
Table 107. Celyad Business Overview
Table 108. Celyad CAR-T Therapy in Haematological Malignancy Product
Table 109. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2018-2023) & (US$ Million)
Table 110. Celyad Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2022 VS 2033
Figure 3. Allogeneic Features
Figure 4. Autologous Features
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2022 VS 2033
Figure 7. Hospitals Case Studies
Figure 8. Cancer Research Centers Case Studies
Figure 9. Others Case Studies
Figure 10. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global CAR-T Therapy in Haematological Malignancy Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Region: 2022 VS 2033
Figure 14. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2022
Figure 15. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2022
Figure 17. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America CAR-T Therapy in Haematological Malignancy Market Share by Country (2018-2033)
Figure 19. United States CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe CAR-T Therapy in Haematological Malignancy Market Share by Country (2018-2033)
Figure 23. Germany CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Share by Region (2018-2033)
Figure 31. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America CAR-T Therapy in Haematological Malignancy Market Share by Country (2018-2033)
Figure 39. Mexico CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Share by Country (2018-2033)
Figure 43. Turkey CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 46. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 47. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 48. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 49. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 50. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 51. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 52. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 53. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 54. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 55. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 56. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 57. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed